Record Q1 revenue and major buybacks at Progyny (NASDAQ: PGNY) shape 2026 outlook
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Progyny, Inc. reported record first quarter 2026 revenue of $328.5 million, up 1.4% year over year and up 12.2% excluding a large client that did not renew for 2025. Gross profit rose to $83.1 million with gross margin improving to 25.3% from 23.4%, reflecting efficiencies and lower stock-based compensation.
Net income increased to $24.2 million, or $0.29 per diluted share, compared with $15.1 million, or $0.17 per diluted share, a year earlier. Adjusted EBITDA was $56.6 million, or a 17.2% margin, slightly below the prior year as higher gross profit was offset by planned platform investments. Operating cash flow was $45.9 million.
The company ended the quarter with $225.1 million in cash, cash equivalents and marketable securities and no debt, after repurchasing more than 5.5 million shares in the quarter and 8.8 million shares cumulatively under its $200 million program, which is now completed. For full year 2026, Progyny projects revenue of $1.365 billion to $1.405 billion, net income of $103.7 million to $112.3 million, and Adjusted EBITDA of $232.0 million to $244.0 million.
Positive
- Strong underlying growth despite client loss: Revenue rose 12.2% year over year after excluding $31.3 million from a large client that did not renew, indicating robust demand from new and existing clients.
- Margin expansion and earnings growth: Gross margin improved from 23.4% to 25.3%, while net income increased to $24.2 million (up from $15.1 million), reflecting better profitability and lower stock-based compensation.
- Significant capital return via buybacks: The company completed its $200 million share repurchase program, retiring 8.8 million shares, including 5.5 million shares bought for $116.4 million in the first quarter.
- Full-year 2026 outlook supports double-digit ex-client growth: Revenue is projected at $1.365–$1.405 billion, or 10.1%–13.3% growth when excluding $48.5 million from the former large client’s transition agreement.
Negative
- None.
Insights
Progyny delivered margin expansion, strong cash generation and double‑digit underlying growth despite a lost large client.
Progyny posted Q1 2026 revenue of $328.5 million, only 1.4% above last year because a large client rolled off. Excluding $31.3 million from that client in the prior year, revenue grew 12.2%, showing solid underlying demand from more clients and covered lives.
Gross profit rose 10% to $83.1 million, and gross margin improved to 25.3% from 23.4%, helped by lower stock-based compensation and operational efficiencies. Net income increased to $24.2 million, or $0.29 per diluted share, while Adjusted EBITDA dipped slightly to $56.6 million as management continued investing in the platform and member experience.
Operating cash flow of $45.9 million and a cash and securities balance of $225.1 million with no debt underpin a strong balance sheet. The completed $200 million repurchase program retired 8.8 million shares, and full‑year 2026 guidance calls for revenue of $1.365–$1.405 billion and Adjusted EBITDA of $232–$244 million, assuming continued client growth and typical utilization patterns.
8-K Event Classification
3 items: 2.02, 7.01, 9.01
3 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Q1 2026 revenue: $328.5 million
Q1 2026 gross margin: 25.3%
Q1 2026 net income: $24.2 million
+5 more
8 metrics
Q1 2026 revenue
$328.5 million
Three months ended March 31, 2026; up 1.4% year over year
Q1 2026 gross margin
25.3%
Improved from 23.4% in Q1 2025
Q1 2026 net income
$24.2 million
Compared with $15.1 million in Q1 2025
Q1 2026 diluted EPS
$0.29 per share
Net income per diluted share for the quarter
Q1 2026 Adjusted EBITDA
$56.6 million
17.2% Adjusted EBITDA margin vs 17.8% a year earlier
Operating cash flow
$45.9 million
Net cash provided by operating activities in Q1 2026
Cash and securities
$225.1 million
Cash, cash equivalents and marketable securities as of March 31, 2026
2026 revenue guidance
$1.365–$1.405 billion
Full year 2026 projected revenue range
Key Terms
Adjusted EBITDA, gross margin, share repurchase program, covered lives, +2 more
6 terms
Adjusted EBITDA financial
"Adjusted EBITDA was $56.6 million, a decrease of 2.1% as compared to the $57.8 million reported"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
gross margin financial
"Gross margin was 25.3%, as compared to 23.4% reported in the prior year."
Gross margin is the difference between how much money a company makes from selling its products and how much it costs to produce them, expressed as a percentage of sales. It shows how efficiently a company is turning sales into profit before other expenses like marketing or salaries. Higher gross margin means the company keeps more money from each sale, which is a good sign of financial health.
covered lives financial
"Once all new clients are live in 2026, the Company continues to anticipate having over 600 clients, representing approximately 7.2 million covered lives."
utilization rate financial
"Represents the member utilization rate for all fertility and family building services, including, but not limited to, ART cycles"
Utilization rate measures the percentage of a company's available capacity that is actually being used over a given period — for example, how full a factory, hospital unit, or loan facility is compared with its maximum. It matters to investors because it signals efficiency and future revenue potential: higher utilization often means better use of fixed costs and stronger demand, while very low or extremely high rates can indicate underuse, lost sales, or strained resources. Think of it like the share of seats filled in a restaurant; it helps show whether the business is making the most of what it has.
revolving credit facility financial
"The Company's $200 million revolving credit facility remains undrawn, and the Company has no planned use for the facility at this time."
A revolving credit facility is a type of loan that a business can borrow from whenever it needs money, up to a set limit. It’s like having a credit card for companies—allowing them to borrow, pay back, and borrow again as needed, providing flexibility for managing cash flow or funding short-term expenses.
Earnings Snapshot
Revenue: $328.5 million · Guidance included
Q1 2026
Revenue
$328.5 million
+1.4% YoY
Net income
$24.2 million
up from $15.1 million in Q1 2025
Diluted EPS
$0.29
up from $0.17 in Q1 2025
Adjusted EBITDA
$56.6 million
-2.1% vs Q1 2025
Gross margin
25.3%
up from 23.4% in Q1 2025
Guidance
For 2026, revenue of $1.365–$1.405 billion, net income of $103.7–$112.3 million, Adjusted EBITDA of $232.0–$244.0 million, and Adjusted EPS of $1.98–$2.09.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 7, 2026
(Exact Name of Registrant as Specified in Charter)
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of Principal Executive Offices) | (Zip Code) | ||||
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition and
Item 7.01 Regulation FD Disclosure.
On May 7, 2026, Progyny, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2026. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
In addition to the press release, a supplemental earnings presentation will be made available on the Company’s investor relations page at investors.progyny.com. A copy of this supplemental earnings presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.
The information furnished under Item 2.02 and Item 7.01, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. | Description | |||||||
99.1 | Press Release of Progyny, Inc. dated May 7, 2026 | |||||||
| 99.2 | First Quarter 2026 Earnings Supplemental Presentation | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Progyny, Inc. | ||||||||
| Date: May 7, 2026 | ||||||||
| By: | /s/ Peter Anevski | |||||||
| Peter Anevski | ||||||||
| Chief Executive Officer | ||||||||
Progyny, Inc. Announces First Quarter 2026 Results
Reports Record First Quarter Revenue of $328.5 Million
Early Selling Season Activity Reflects Robust Demand for Women's Health and Family Building Solutions
Returned Value to Shareholders Through Repurchase of 8.8 Million Shares to Date Since November
NEW YORK, May 7, 2026 /GlobeNewswire/ - Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended March 31, 2026 (“the first quarter of 2026”), as compared to the three-month period ended March 31, 2025 (“the first quarter of 2025” or “the prior year period”).
“We're pleased with the strong start to the year, as member engagement trended to the higher end of our expectations, reflecting that people are pursuing the services they need in order to address their family building and overall health and well-being goals,” said Pete Anevski, Chief Executive Officer of Progyny.
“The CDC recently reported that, while overall birth rates in the US continued to decline in 2025 - extending a trend that began nearly two decades ago - the only age cohorts to increase were women 30 and over. Women over 30 have been accounting for more than half of all births since 2021, and now comprise their highest proportion of total births ever,” continued Anevski. “These macro shifts reflect how society has increasingly deferred family building to later in life, when natural conception becomes more difficult for many, thereby increasing the demand for fertility benefits solutions that can cost-effectively address this fundamental need.
“For more than a decade, Progyny has been meeting this need with our solutions, which are proven to drive favorable clinical outcomes and overall cost containment for both the employer and the patient. This is just one reason why our programs continue to be a priority for all types of companies. Our current selling season is in its early stages and we're off to a good start. Activity is healthy, overall pipeline and the early build of new pipeline is substantially favorable versus a year ago, and early commitments are pacing ahead of this time last year, all of which positions us well for this selling season.”
“This quarter's results reflect topline growth, increased gross margin, and a high conversion of Adjusted EBITDA to operating cash flow. During the quarter, we also continued to make our planned investments to further enhance both our platform and the member experience,” said Mark Livingston, Chief Financial Officer of Progyny. “Additionally, through the share repurchase program that began in November, we returned value to our investors by repurchasing 8.8 million shares.”
First Quarter 2026 Highlights:
| (unaudited; in thousands, except per share amounts) | 1Q 2026 | 1Q 2025 | |||||||||
Revenue | $328,504 | $324,038 | |||||||||
Gross Profit | $83,071 | $75,795 | |||||||||
Gross Margin | 25.3% | 23.4% | |||||||||
Net Income | $24,232 | $15,059 | |||||||||
Net Income per Diluted Share1 | $0.29 | $0.17 | |||||||||
Adjusted Earnings per Diluted Share2 | $0.50 | $0.48 | |||||||||
Adjusted EBITDA2 | $56,583 | $57,790 | |||||||||
Adjusted EBITDA Margin2 | 17.2% | 17.8% | |||||||||
1.Net income per diluted share reflects weighted-average shares outstanding as adjusted for potential dilutive securities, including options, restricted stock units, and shares issuable under the employee stock purchase plan.
2.Adjusted Earnings per Diluted Share, Adjusted EBITDA, and Adjusted EBITDA margin are financial measures that are not required by, or presented in accordance with U.S. generally accepted accounting principles ("GAAP"). Please see Annex A of this press release for a reconciliation of Adjusted Earnings per Diluted Share to earnings per share, and Adjusted EBITDA to net income, the most directly comparable financial measures stated in accordance with GAAP for each of the
1
periods presented. We calculate Adjusted Earnings per Diluted Share as net income per diluted share excluding the impact of stock-based compensation, adjusted for the impact of taxes. We calculate Adjusted EBITDA margin as Adjusted EBITDA divided by revenue.
Financial Highlights
Revenue was $328.5 million, a 1.4% increase as compared to the $324.0 million reported in the first quarter of 2025, as the increase in our number of clients and covered lives was largely offset by the impact of the previously disclosed large client who did not renew its services for 2025, though it provided for an extended transition period over the first half of 2025 for members meeting certain criteria. There was no contribution from this client in the first quarter of 2026, and excluding the $31.3 million of revenue from this client in the prior year period, revenue increased 12.2%.
•Fertility benefit services revenue was $209.4 million, a 1.5% increase from the $206.4 million reported in the first quarter of 2025.
•Pharmacy benefit services revenue was $119.1 million, a 1.3% increase as compared to the $117.6 million reported in the first quarter of 2025.
Gross profit was $83.1 million, an increase of 10% from the $75.8 million reported in the first quarter of 2025, reflecting ongoing efficiencies realized in the delivery of our care management services as well as a decrease in stock based compensation expense. Gross margin was 25.3%, as compared to 23.4% reported in the prior year.
Net income was $24.2 million, or $0.29 income per diluted share, as compared to the $15.1 million, or $0.17 income per diluted share, reported in the first quarter of 2025. The higher net income was due primarily to the higher operating profit and lower stock based compensation expense, which was partially offset by lower interest and other income, net, as well as a higher provision for income taxes.
Adjusted EBITDA was $56.6 million, a decrease of 2.1% as compared to the $57.8 million reported in the first quarter of 2025, as the higher gross profit was more than offset by planned investments to expand the features and functionality of our platform. Adjusted EBITDA margin was 17.2% as compared to the 17.8% Adjusted EBITDA margin in the first quarter of 2025. Refer to Annex A for a reconciliation of Adjusted EBITDA to net income.
Cash Flow
Net cash provided by operating activities in the first quarter of 2026 was $45.9 million, as compared to $49.8 million provided by operating activities in the prior year period. Cash flow reflects the timing impact of certain working capital items in both periods as well as the customary build in accounts receivable in the first quarter of the year as we establish the payment flows for our newest clients.
Balance Sheet and Financial Position
As of March 31, 2026, the Company had total working capital of approximately $265.8 million and no debt. This included cash and cash equivalents and marketable securities of $225.1 million, a decrease of $85.0 million from the balances as of December 31, 2025 due principally to share repurchase activity during the quarter. The Company's $200 million revolving credit facility remains undrawn, and the Company has no planned use for the facility at this time.
Share Repurchase Activity
During the first quarter of 2026, the Company purchased more than 5.5 million shares of its common stock for a total cost of $116.4 million through its November 2025 share repurchase program, which provided for a total authorization of up to $200 million. The Company purchased a cumulative 8.8 million shares of its common stock under the program, and as of March 31, 2026, the program was completed and no amounts remained available for repurchase.
The Company's Board is currently evaluating potential options for a new share repurchase program. We anticipate a decision around the end of May, and the Company expects to make an announcement at that time.
2
Key Metrics
The Company had 595 fertility and family building clients as of March 31, 2026, as compared to 532 clients as of March 31, 2025.
| Three Months Ended March 31, | |||||||||||
| 2026 | 2025 | ||||||||||
Assisted Reproductive Treatment (ART) Cycles(*) | 15,647 | 16,160 | |||||||||
Utilization - All Members(**) | 0.56% | 0.54% | |||||||||
Utilization - Female Only(**) | 0.48% | 0.46% | |||||||||
Average Members(***) | 7,185,000 | 6,695,000 | |||||||||
* Represents the number of ART cycles performed, including IVF with a fresh embryo transfer, IVF freeze all cycles/embryo banking, frozen embryo transfers, and egg freezing. Includes ART cycles performed in the first half of 2025 under the extended transition of care agreement with the large client who did not renew its service agreement.
** Represents the member utilization rate for all fertility and family building services, including, but not limited to, ART cycles, initial consultations, IUIs, and genetic testing. The utilization rate for all members includes all unique members (female and male) who utilize the benefit during that period, while the utilization rate for female only includes only unique females who utilize the benefit during that period. For purposes of calculating utilization rates in any given period, the results reflect the number of unique members utilizing the benefit for that period. Individual periods cannot be combined as member treatments may span multiple periods. Utilization for 2025 excludes activity under the extended transition of care agreement that ended June 30, 2025 with the large client who did not renew its service agreement, as only members meeting certain criteria were eligible to use the benefit.
***Includes approximately 300,000 members from a single client who are not reflected in utilization as a result of the client's chosen benefit design. 2025 excludes the limited number of members who were eligible to use the benefit under the extended transition of care agreement that ended June 30, 2025 with the large client who did not renew its service agreement.
Financial Outlook
The majority of the clients that were added in the most recent selling season went live in the first quarter of 2026, with a handful of additional clients expected to launch their benefit in the second quarter. Once all new clients are live in 2026, the Company continues to anticipate having over 600 clients, representing approximately 7.2 million covered lives.
As the second quarter begins, member engagement is pacing consistent with the typical seasonal patterns following the start of the year. Given the variability in member engagement experienced in prior periods, as well as the potential for any impact from ongoing macroeconomic uncertainty, the guidance issued today reflects a range of member engagement. The ranges also reflect the impact of the Company's previously announced investments in member experience.
The Company is providing the following financial guidance for both the three-month and full year periods ending June 30, 2026.
•Full Year 2026 Outlook:
oRevenue is now projected to be $1.365 billion to $1.405 billion, reflecting growth of 5.9% to 9.0%; excluding the $48.5 million of revenue in 2025 from the large client who was under a transition agreement in the first half of 2025, revenue is expected to increase by 10.1% to 13.3%
oNet income is projected to be $103.7 million to $112.3 million, or $1.23 to $1.34 per diluted share, on the basis of approximately 84 million assumed weighted-average fully diluted-shares outstanding
oAdjusted EBITDA1 is projected to be $232.0 million to $244.0 million
oAdjusted earnings per diluted share1 is projected to be $1.98 to $2.09
•Second Quarter of 2026 Outlook:
oRevenue is projected to be $342.0 million to $355.0 million, reflecting growth of 2.7% to 6.6%; excluding the $17.2 million of revenue in 2025 from the large client who was under a transition agreement in the first half of 2025, revenue is expected to increase by 8.3% to 12.4%
oNet income is projected to be $25.8 million to $28.7 million, or $0.31 to $0.35 per diluted share, on the basis of approximately 83 million assumed weighted-average fully diluted-shares outstanding
3
oAdjusted EBITDA1 is projected to be $58.0 million to $62.0 million
oAdjusted earnings per diluted share1 is projected to be $0.50 to $0.53
1.Adjusted EBITDA and Adjusted earnings per diluted share are financial measures that are not required by, or presented in accordance with, GAAP. Please see Annex A of this press release for a reconciliation of forward-looking Adjusted EBITDA to forward-looking net income and Adjusted net income to net income, the most directly comparable financial measures stated in accordance with GAAP, for the period presented.
Conference Call Information
Progyny will host a conference call at 4:45 P.M. Eastern Time (1:45 P.M. Pacific Time) today, May 7, 2026, to discuss its financial results. Interested participants from the United States may join by calling 1.866.825.7331 and using conference ID 265484. Participants from international locations may join by calling 1.973.413.6106 and using the same conference ID. A replay of the call will be available until May 14, 2026 at 5:00 P.M. Eastern Time by dialing 1.800.332.6854 (U.S. participants) or 1.973.528.0005 (international) and entering passcode 265484. A live audio webcast of the call and subsequent replay will also be available through the Events & Presentations section of the Company’s Investor Relations website at investors.progyny.com.
About Progyny
Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients, and physicians.
Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.
Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare’s Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, INC. 5000, INC. Power Partners and Crain’s Fast 50 for NYC. For more information, visit www.progyny.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our financial outlook for the second quarter and full year 2026, including the impact of our sales season and client launches; our anticipated number of clients and covered lives for 2026; our expected utilization rates and mix; the demand for our solutions; our expectations for our selling season for 2027 launches; our positioning to successfully manage economic uncertainty on our business; the timing of client decisions; our ability to retain existing clients and acquire new clients; and our business strategy, plans, goals and expectations concerning our market position, future operations, and other financial and operating information. The words “anticipates,” “assumes,” “believe,” “contemplate,” “continues, ” “could,” “estimates,” “expects,” “future,” “intends,” “may,” “plans,” “predict,” “potential,” “project,” “seeks,” “should,” “target,” “will,” and the negative of these or similar expressions and phrases are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions.
Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, without limitation, failure to meet our publicly announced guidance or
4
other expectations about our business; competition in the market in which we operate; our history of operating losses and ability to sustain profitability; unfavorable conditions in our industry or the United States economy; our limited operating history and the difficulty in predicting our future results of operations; our ability to attract and retain clients and increase the adoption of services within our client base; the loss of any of our largest client accounts; changes in the technology industry; changes or developments in the health insurance market; negative publicity in the health benefits industry; lags, failures or security breaches in our computer systems or those of our vendors; a significant change in the utilization of our solutions; our ability to offer high-quality support; positive references from our existing clients; our ability to develop and expand our marketing and sales capabilities; the rate of growth of our future revenue; the accuracy of the estimates and assumptions we use to determine the size of target markets; our ability to successfully manage our growth; reductions in employee benefits spending; seasonal fluctuations in our sales; the adoption of new solutions and services by our clients or members; our ability to innovate and develop new offerings; our ability to adapt and respond to the changing medical landscape, regulations, and client needs, requirements or preferences; our ability to maintain and enhance our brand; our ability to attract and retain members of our management team, key employees, or other qualified personnel; risks related to any litigation against us; our ability to maintain our Center of Excellence network of healthcare providers; our strategic relationships with and monitoring of third parties; our ability to maintain our pharmacy distribution network if there is a disruption to our network or its associated supply chains; our relationship with key pharmacy program partners or any decline in rebates provided by them; our ability to maintain our relationships with benefits consultants; exposure to credit risk from our members; risks related to government regulation; risks related to our business with government entities; our ability to protect our intellectual property rights; risks related to acquisitions, strategic investments, or partnerships; federal tax reform and changes to our effective tax rate; the imposition of state and local state taxes; our ability to utilize a portion of our net operating loss or research tax credit carryforwards; our ability to develop or maintain effective internal control over financial reporting; and our ability to adapt and respond to the changing SEC or stakeholder expectations regarding environmental, social and governance practices. For a detailed discussion of these and other risk factors, please refer to our filings with the Securities and Exchange Commission (the “SEC”), including in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and subsequent reports that we file with the SEC, which are available at http://investors.progyny.com and on the SEC’s website at https://www.sec.gov.
Forward-looking statements represent our management’s beliefs and assumptions only as of the date of this press release. Our actual future results could differ materially from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons.
Non-GAAP Financial Measures
In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), this press release and the accompanying tables include the non-GAAP financial measures Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted earnings per diluted share.
Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted earnings per diluted share are supplemental financial measures that are not required by, or presented in accordance with, GAAP. We believe that these non-GAAP measures, when taken together with our GAAP financial results, provide meaningful supplemental information regarding our operating performance and facilitates internal comparisons of our historical operating performance on a more consistent basis by excluding certain items that may not be indicative of our business, results of operations or outlook. In particular, we believe that the use of Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted earnings per diluted share are helpful to our investors as they are measures used by management in assessing the health of our business, determining incentive compensation, evaluating our operating performance, and for internal planning and forecasting purposes.
Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted earnings per diluted share are presented for supplemental informational purposes only, have limitations as analytical tools and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Some of the limitations of
5
Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted earnings per diluted share include: (1) it does not properly reflect capital commitments to be paid in the future; (2) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures; (3) it does not consider the impact of stock-based compensation expense; (4) it does not reflect other non-operating income and expenses, including interest and other income, net; and (5) it does not reflect tax payments that may represent a reduction in cash available to us. In addition, our non-GAAP measures may not be comparable to similarly titled measures of other companies because they may not calculate such measures in the same manner as we calculate these measures, limiting their usefulness as comparative measures. Because of these limitations, when evaluating our performance, you should consider Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted earnings per diluted share alongside other financial performance measures, including our net income, gross margin, and our other GAAP results.
We calculate Adjusted EBITDA as net income, adjusted to exclude depreciation and amortization; stock-based compensation expense; interest and other income, net; and provision for income taxes. We calculate Adjusted EBITDA margin as Adjusted EBITDA divided by revenue. We calculate Adjusted earnings per diluted share as net income per diluted share excluding the impact of stock-based compensation, adjusted for the associated impact of taxes. Please see Annex A: “Reconciliation of GAAP to Non-GAAP Financial Measures” elsewhere in this press release.
For Further Information, Please Contact:
Investors:
James Hart
investors@progyny.com
Media:
Alexis Ford
media@progyny.com
6
PROGYNY, INC.
Consolidated Balance Sheets
(Unaudited)
(in thousands, except share and per share amounts)
| March 31, | December 31, | ||||||||||
| 2026 | 2025 | ||||||||||
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 131,607 | $ | 112,238 | |||||||
| Marketable securities | 93,504 | 197,858 | |||||||||
Accounts receivable, net of $56,300 and $55,659 of allowances at March 31, 2026 and December 31, 2025, respectively | 263,613 | 220,287 | |||||||||
| Prepaid expenses and other current assets | 12,827 | 21,392 | |||||||||
| Total current assets | 501,551 | 551,775 | |||||||||
| Property and equipment, net | 35,709 | 29,927 | |||||||||
| Operating lease right-of-use assets | 24,275 | 24,990 | |||||||||
| Goodwill | 19,879 | 19,978 | |||||||||
| Intangible assets, net | 5,971 | 6,216 | |||||||||
Deferred tax assets, net | 93,080 | 93,013 | |||||||||
| Other noncurrent assets | 17,872 | 16,536 | |||||||||
| Total assets | $ | 698,337 | $ | 742,435 | |||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 157,826 | $ | 124,071 | |||||||
| Accrued expenses and other current liabilities | 77,916 | 78,320 | |||||||||
| Total current liabilities | 235,742 | 202,391 | |||||||||
| Operating lease noncurrent liabilities | 23,251 | 24,000 | |||||||||
| Total liabilities | 258,993 | 226,391 | |||||||||
| Commitments and Contingencies | |||||||||||
| STOCKHOLDERS' EQUITY | |||||||||||
Common stock, $0.0001 par value; 1,000,000,000 shares authorized; at March 31, 2026 and December 31, 2025, respectively; 99,465,999 and 99,049,485 shares issued; 78,270,386 and 83,365,696 outstanding at March 31, 2026 and December 31, 2025, respectively | 9 | 9 | |||||||||
| Additional paid-in capital | 717,759 | 700,785 | |||||||||
Treasury stock, at cost, $0.0001 par value; 21,811,593 and 16,299,769 shares at March 31, 2026 and December 31, 2025, respectively | (505,760) | (388,075) | |||||||||
| Accumulated earnings | 227,059 | 202,827 | |||||||||
| Accumulated other comprehensive income | 277 | 498 | |||||||||
| Total stockholders’ equity | 439,344 | 516,044 | |||||||||
| Total liabilities and stockholders’ equity | $ | 698,337 | $ | 742,435 | |||||||
7
PROGYNY, INC.
Consolidated Statements of Operations
(Unaudited)
(in thousands, except share and per share amounts)
| Three Months Ended March 31, | |||||||||||
| 2026 | 2025 | ||||||||||
| Revenue | $ | 328,504 | $ | 324,038 | |||||||
| Cost of services | 245,433 | 248,243 | |||||||||
| Gross profit | 83,071 | 75,795 | |||||||||
| Operating expenses: | |||||||||||
| Sales and marketing | 16,884 | 17,786 | |||||||||
| General and administrative | 30,808 | 33,839 | |||||||||
| Total operating expenses | 47,692 | 51,625 | |||||||||
| Income from operations | 35,379 | 24,170 | |||||||||
| Interest and other income, net | 1,504 | 2,367 | |||||||||
| Income before income taxes | 36,883 | 26,537 | |||||||||
| Provision for income taxes | 12,651 | 11,478 | |||||||||
| Net income | $ | 24,232 | $ | 15,059 | |||||||
| Net income per share: | |||||||||||
| Basic | $ | 0.30 | $ | 0.18 | |||||||
| Diluted | $ | 0.29 | $ | 0.17 | |||||||
| Weighted-average shares used in computing net income per share: | |||||||||||
| Basic | 80,920,993 | 85,499,153 | |||||||||
| Diluted | 84,755,262 | 89,307,934 | |||||||||
8
PROGYNY, INC.
Consolidated Statements of Cash Flows
(Unaudited)
(in thousands)
| Three Months Ended March 31, | ||||||||||||||
| 2026 | 2025 | |||||||||||||
| OPERATING ACTIVITIES | ||||||||||||||
| Net income | $ | 24,232 | $ | 15,059 | ||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||||
| Deferred tax expense | 10 | 11 | ||||||||||||
| Non-cash interest expense | 279 | — | ||||||||||||
| Depreciation and amortization | 1,483 | 1,108 | ||||||||||||
| Loss on disposal of property and equipment | 52 | 79 | ||||||||||||
| Stock-based compensation expense | 19,721 | 32,512 | ||||||||||||
| Bad debt expense | 4,436 | 5,659 | ||||||||||||
| Net accretion of discounts on marketable securities | 1,150 | 1,106 | ||||||||||||
| Changes in operating assets and liabilities: | ||||||||||||||
| Accounts receivable | (47,773) | (69,732) | ||||||||||||
| Prepaid expenses and other current assets | 9,601 | (2,383) | ||||||||||||
| Accounts payable | 33,635 | 49,618 | ||||||||||||
| Accrued expenses and other current liabilities | 1,530 | 17,509 | ||||||||||||
| Other noncurrent assets and liabilities | (2,407) | (738) | ||||||||||||
| Net cash provided by operating activities | 45,949 | 49,808 | ||||||||||||
| INVESTING ACTIVITIES | ||||||||||||||
| Purchase of property and equipment, net | (6,347) | (2,843) | ||||||||||||
| Purchase of marketable securities | — | (145,809) | ||||||||||||
| Sale of marketable securities | 102,941 | 63,382 | ||||||||||||
| Acquisition of business, net of cash acquired | — | (9,340) | ||||||||||||
| Net cash provided by (used in) investing activities | 96,594 | (94,610) | ||||||||||||
| FINANCING ACTIVITIES | ||||||||||||||
| Repurchase of common stock | (118,607) | — | ||||||||||||
| Proceeds from exercise of stock options | 30 | 39 | ||||||||||||
| Payment of employee taxes related to equity awards | (4,844) | (3,583) | ||||||||||||
| Proceeds from contributions to employee stock purchase plan | 307 | 256 | ||||||||||||
| Net cash used in financing activities | (123,114) | (3,288) | ||||||||||||
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | (51) | 15 | ||||||||||||
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 19,378 | (48,075) | ||||||||||||
| Cash, cash equivalents, and restricted cash, beginning of period | 114,193 | 162,314 | ||||||||||||
| Cash, cash equivalents, and restricted cash, end of period | $ | 133,571 | $ | 114,239 | ||||||||||
| Cash and cash equivalents | $ | 131,607 | $ | 109,239 | ||||||||||
| Restricted cash included within current assets | 1,039 | — | ||||||||||||
| Restricted cash included within noncurrent assets | 925 | 5,000 | ||||||||||||
| Total cash, cash equivalents, and restricted cash | $ | 133,571 | $ | 114,239 | ||||||||||
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | ||||||||||||||
| Cash paid for income taxes, net of refunds received | $ | 640 | $ | 400 | ||||||||||
| SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES | ||||||||||||||
| Additions of property and equipment, net included in accounts payable and accrued expenses | $ | 812 | $ | 1,246 | ||||||||||
9
ANNEX A
PROGYNY, INC.
Reconciliation of GAAP to Non-GAAP Financial Measures
-(unaudited)
(in thousands, except share and per share amounts)
Costs of Services, Gross Margin and Operating Expenses Excluding Stock-Based Compensation Calculation
The following table provides a reconciliation of cost of services, gross profit, sales and marketing and general and administrative expenses to each of these measures excluding the impact of stock-based compensation expense for each of the periods presented:
| Three Months Ended | ||||||||||||||||||||
| March 31, 2026 | ||||||||||||||||||||
| GAAP | Stock-Based Compensation Expense | Non-GAAP | ||||||||||||||||||
| Cost of services | $ | 245,433 | $ | (6,270) | $ | 239,163 | ||||||||||||||
| Gross profit | $ | 83,071 | $ | 6,270 | $ | 89,341 | ||||||||||||||
| Sales and marketing | $ | 16,884 | $ | (5,555) | $ | 11,329 | ||||||||||||||
| General and administrative | $ | 30,808 | $ | (7,896) | $ | 22,912 | ||||||||||||||
| Expressed as a Percentage of Revenue | ||||||||||||||||||||
| Gross margin | 25.3 | % | 1.9 | % | 27.2 | % | ||||||||||||||
| Sales and marketing | 5.1 | % | (1.7 | %) | 3.4 | % | ||||||||||||||
| General and administrative | 9.4 | % | (2.4 | %) | 7.0 | % | ||||||||||||||
| Three Months Ended | ||||||||||||||||||||
| March 31, 2025 | ||||||||||||||||||||
| GAAP | Stock-Based Compensation Expense | Non-GAAP | ||||||||||||||||||
| Cost of services | $ | 248,243 | $ | (9,398) | $ | 238,845 | ||||||||||||||
| Gross profit | $ | 75,795 | $ | 9,398 | $ | 85,193 | ||||||||||||||
| Sales and marketing | $ | 17,786 | $ | (7,875) | $ | 9,911 | ||||||||||||||
| General and administrative | $ | 33,839 | $ | (15,239) | $ | 18,600 | ||||||||||||||
| Expressed as a Percentage of Revenue | ||||||||||||||||||||
| Gross margin | 23.4 | % | 2.9 | % | 26.3 | % | ||||||||||||||
| Sales and marketing | 5.5 | % | (2.4 | %) | 3.1 | % | ||||||||||||||
| General and administrative | 10.4 | % | (4.7 | %) | 5.7 | % | ||||||||||||||
Note: percentages shown in the table may not cross foot due to rounding.
10
Adjusted Earnings Per Diluted Share Calculation
The following table provides a reconciliation of net income to Adjusted Earnings Per Diluted Share for each of the periods presented:
| Three months ended | ||||||||||||||
| March 31, | ||||||||||||||
| 2026 | 2025 | |||||||||||||
| Net Income | $ | 24,232 | $ | 15,059 | ||||||||||
| Add: | ||||||||||||||
| Stock-based compensation expense | 19,721 | 32,512 | ||||||||||||
| Income tax effect of non-GAAP adjustment | (1,940) | (4,523) | ||||||||||||
| Adjusted Net income | $ | 42,013 | $ | 43,048 | ||||||||||
| Diluted Shares | 84,755,262 | 89,307,934 | ||||||||||||
| Adjusted Earnings Per Diluted Share | $ | 0.50 | $ | 0.48 | ||||||||||
Adjusted EBITDA Calculation
The following table provides a reconciliation of net income to Adjusted EBITDA for each of the periods presented:
| Three Months Ended | ||||||||||||||
| March 31, | ||||||||||||||
| 2026 | 2025 | |||||||||||||
| Net income | $ | 24,232 | $ | 15,059 | ||||||||||
| Add: | ||||||||||||||
| Depreciation and amortization | 1,483 | 1,108 | ||||||||||||
| Stock‑based compensation expense | 19,721 | 32,512 | ||||||||||||
| Interest and other income, net | (1,504) | (2,367) | ||||||||||||
| Provision for income taxes | 12,651 | 11,478 | ||||||||||||
| Adjusted EBITDA | $ | 56,583 | $ | 57,790 | ||||||||||
11
Reconciliation of Non-GAAP Financial Guidance for the Three Months Ending June 30, 2026 and Year Ending December 31, 2026
| Three Months Ending June 30, 2026 | Year Ending December 31, 2026 | |||||||||||||||||||||||||
| Low | High | Low | High | |||||||||||||||||||||||
| Revenue | $ | 342,000 | $ | 355,000 | $ | 1,365,000 | $ | 1,405,000 | ||||||||||||||||||
| Net Income | $ | 25,800 | $ | 28,700 | $ | 103,700 | $ | 112,300 | ||||||||||||||||||
| Add: | ||||||||||||||||||||||||||
| Depreciation and amortization | 2,500 | 2,500 | 11,000 | 11,000 | ||||||||||||||||||||||
| Stock-based compensation expense | 21,000 | 21,000 | 80,000 | 80,000 | ||||||||||||||||||||||
| Interest and other income, net | (1,600) | (1,600) | (7,000) | (7,000) | ||||||||||||||||||||||
| Provision for income taxes | 10,300 | 11,400 | 44,300 | 47,700 | ||||||||||||||||||||||
| Adjusted EBITDA* | $ | 58,000 | $ | 62,000 | $ | 232,000 | $ | 244,000 | ||||||||||||||||||
| Three Months Ending June 30, 2026 | Year Ending December 31, 2026 | |||||||||||||||||||||||||
| Low | High | Low | High | |||||||||||||||||||||||
| Net Income | $ | 25,800 | $ | 28,700 | $ | 103,700 | $ | 112,300 | ||||||||||||||||||
| Add: | ||||||||||||||||||||||||||
| Stock-based compensation | 21,000 | 21,000 | 80,000 | 80,000 | ||||||||||||||||||||||
| Income tax effect of non-GAAP adjustment | (5,300) | (5,300) | (17,000) | (17,000) | ||||||||||||||||||||||
| Adjusted Net income* | $ | 41,500 | $ | 44,400 | $ | 166,700 | $ | 175,300 | ||||||||||||||||||
| Diluted Shares | 83,000,000 | 83,000,000 | 84,000,000 | 84,000,000 | ||||||||||||||||||||||
| Adjusted Earnings Per Diluted Share | $ | 0.50 | $ | 0.53 | $ | 1.98 | $ | 2.09 | ||||||||||||||||||
* All of the numbers in the tables above reflect our future outlook as of the date hereof. Net income, Adjusted Net Income and Adjusted EBITDA ranges do not reflect any estimate for other potential activities and transactions, nor do they contemplate any discrete income tax items, including the income tax impact related to equity compensation activity.
12
Assisted Reproductive Technology (ART) Cycles per Unique Female Utilizer
The following tables provide historical trend and guidance assumptions for average members, female utilization rate, and ART Cycles per Unique Female Utilizer for the full year and quarterly periods presented:
| Guidance Assumptions For: | ||||||||||||||||||||||||||||||||||||||||||||
| Year Ending December 31, 2026 | ||||||||||||||||||||||||||||||||||||||||||||
| Year Ending December 31, | Low End as of | High End as of | ||||||||||||||||||||||||||||||||||||||||||
| 2021 | 2022 | 2023 | 2024 1 | 2025 1 | May 7, 20261 | May 7, 20261 | ||||||||||||||||||||||||||||||||||||||
| Average Members | 2,812,000 | 4,349,000 | 5,383,000 | 6,104,0001 | 6,419,0001 | 6,900,0001 | 6,900,0001 | |||||||||||||||||||||||||||||||||||||
| Female Utilization Rate | 1.07 | % | 1.03 | % | 1.09 | % | 1.07 | % | 1.04%2 | 1.04 | % | 1.05 | % | |||||||||||||||||||||||||||||||
| Female Unique Utilizers | 30,053 | 44,600 | 58,596 | 65,077 | 66,7732 | 72,000 | 72,500 | |||||||||||||||||||||||||||||||||||||
| ART Cycles | 28,413 | 42,598 | 58,013 | 61,114 | 65,006 | 67,000 | 69,100 | |||||||||||||||||||||||||||||||||||||
| ART Cycles per Unique Female Utilizer | 0.95 | 0.96 | 0.99 | 0.94 | 0.93 | 0.93 | 0.95 | |||||||||||||||||||||||||||||||||||||
| Revenue ($ in millions) | $500.6 | $786.9 | $1,088.6 | $1,167.2 | $1,288.7 | $1,365.0 | $1,405.0 | |||||||||||||||||||||||||||||||||||||
1 Calculations for 2024, 2025, and 2026 exclude approximately 300,000 members from a single client not reflected in female utilizers as a result of the client's chosen benefit design.
2 Calculations exclude activity from a large client whose program discontinued for 2025, but who allowed for an extended period of transition of care for certain members during the first half of 2025.
Quarterly ART Cycles per Unique Female Utilizer
| Three Months Ending | Year Ending | |||||||||||||||||||||||||||||||
| March 31, | June 30, | September 30, | December 31, | December 31, | ||||||||||||||||||||||||||||
| 2022 | 0.50 | 0.55 | 0.56 | 0.58 | 0.96 | |||||||||||||||||||||||||||
| 2023 | 0.51 | 0.55 | 0.56 | 0.58 | 0.99 | |||||||||||||||||||||||||||
| 2024* | 0.53 | 0.54 | 0.52 | 0.54 | 0.94 | |||||||||||||||||||||||||||
| 2025* | 0.51 | 0.52 | 0.52 | 0.52 | 0.93 | |||||||||||||||||||||||||||
| 2026: Low End of Guidance Range* | 0.48 | 0.50E | 0.93E | |||||||||||||||||||||||||||||
| 2026: High End of Guidance Range* | 0.48 | 0.51E | 0.95E | |||||||||||||||||||||||||||||
*Calculations for 2024, 2025, and 2026 exclude approximately 300,000 members from a single client not reflected in female utilizers as a result of the client's chosen benefit design.
E indicates the estimated value assumed.
13
P L E A S E R E F E R T O S L I D E 2 F O R T H E S A F E H A R B O R L A N G U AG E R E G A R D I N G T H I S P R E S E N T A T I O N1 1st Quarter 2026 Earnings Supplement May 2026
P L E A S E R E F E R T O S L I D E 2 F O R T H E S A F E H A R B O R L A N G U AG E R E G A R D I N G T H I S P R E S E N T A T I O N2 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this presentation other than statements of historical fact, including, without limitation, statements regarding our financial outlook for the second quarter and full year 2026, including the impact of our sales season and client launches; our anticipated number of clients and covered lives for 2026; our expected utilization rates and mix; the demand for our solutions; our expectations for our selling season for 2027 launches; our positioning to successfully manage economic uncertainty on our business; the timing of client decisions; our ability to retain existing clients and acquire new clients; and our business strategy, plans, goals and expectations concerning our market position, future operations, and other financial and operating information. The words “anticipates,” “assumes,” “believe,” “contemplate,” “continues, ” “could,” “estimates,” “expects,” “future,” “intends,” “may,” “plans,” “predict,” “potential,” “project,” “seeks,” “should,” “target,” “will,” and the negative of these or similar expressions and phrases are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, without limitation, failure to meet our publicly announced guidance or other expectations about our business; competition in the market in which we operate; our history of operating losses and ability to sustain profitability; unfavorable conditions in our industry or the United States economy; our limited operating history and the difficulty in predicting our future results of operations; our ability to attract and retain clients and increase the adoption of services within our client base; the loss of any of our largest client accounts; changes in the technology industry; changes or developments in the health insurance market; negative publicity in the health benefits industry; lags, failures or security breaches in our computer systems or those of our vendors; a significant change in the utilization of our solutions; our ability to offer high-quality support; positive references from our existing clients; our ability to develop and expand our marketing and sales capabilities; the rate of growth of our future revenue; the accuracy of the estimates and assumptions we use to determine the size of target markets; our ability to successfully manage our growth; reductions in employee benefits spending; seasonal fluctuations in our sales; the adoption of new solutions and services by our clients or members; our ability to innovate and develop new offerings; our ability to adapt and respond to the changing medical landscape, regulations, and client needs, requirements or preferences; our ability to maintain and enhance our brand; our ability to attract and retain members of our management team, key employees, or other qualified personnel; risks related to any litigation against us; our ability to maintain our Center of Excellence network of healthcare providers; our strategic relationships with and monitoring of third parties; our ability to maintain our pharmacy distribution network if there is a disruption to our network or its associated supply chains; our relationship with key pharmacy program partners or any decline in rebates provided by them; our ability to maintain our relationships with benefits consultants; exposure to credit risk from our members; risks related to government regulation; risks related to our business with government entities; our ability to protect our intellectual property rights; risks related to acquisitions, strategic investments, or partnerships; federal tax reform and changes to our effective tax rate; the imposition of state and local state taxes; our ability to utilize a portion of our net operating loss or research tax credit carryforwards; our ability to develop or maintain effective internal control over financial reporting; and our ability to adapt and respond to the changing SEC or stakeholder expectations regarding environmental, social and governance practices. For a detailed discussion of these and other risk factors, please refer to our filings with the Securities and Exchange Commission (the “SEC”), including in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and subsequent reports that we file with the SEC, which are available at http://investors.progyny.com and on the SEC’s website at https://www.sec.gov. Forward-looking statements represent our management’s beliefs and assumptions only as of the date of this presentation. Our actual future results could differ materially from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons. Non-GAAP Financial Measures: In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), this presentation and the accompanying tables include the non-GAAP financial measures Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted earnings per diluted share. Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted earnings per diluted share are supplemental financial measures that are not required by, or presented in accordance with, GAAP. We believe that these non-GAAP measures, when taken together with our GAAP financial results, provide meaningful supplemental information regarding our operating performance and facilitates internal comparisons of our historical operating performance on a more consistent basis by excluding certain items that may not be indicative of our business, results of operations or outlook. In particular, we believe that the use of Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted earnings per diluted share are helpful to our investors as they are measures used by management in assessing the health of our business, determining incentive compensation, evaluating our operating performance, and for internal planning and forecasting purposes. Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted earnings per diluted share are presented for supplemental informational purposes only, have limitations as analytical tools and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Some of the limitations of Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted earnings per diluted share include: (1) it does not properly reflect capital commitments to be paid in the future; (2) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures; (3) it does not consider the impact of stock-based compensation expense; (4) it does not reflect other non-operating income and expenses, including interest and other income, net; and (5) it does not reflect tax payments that may represent a reduction in cash available to us. In addition, our non-GAAP measures may not be comparable to similarly titled measures of other companies because they may not calculate such measures in the same manner as we calculate these measures, limiting their usefulness as comparative measures. Because of these limitations, when evaluating our performance, you should consider Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted earnings per diluted share alongside other financial performance measures, including our net income, gross margin, and our other GAAP results. We calculate Adjusted EBITDA as net income, adjusted to exclude depreciation and amortization; stock-based compensation expense; interest and other income, net; and provision for income taxes. We calculate Adjusted EBITDA margin as Adjusted EBITDA divided by revenue. We calculate Adjusted earnings per diluted share as net income per diluted share excluding the impact of stock-based compensation, adjusted for the associated impact of taxes. Please see the Appendix “Reconciliation of GAAP to Non-GAAP Financial Measures” and “Reconciliation of Non-GAAP Financial Guidance” in this presentation.
P L E A S E R E F E R T O S L I D E 2 F O R T H E S A F E H A R B O R L A N G U AG E R E G A R D I N G T H I S P R E S E N T A T I O N3 1st Quarter 2026 Results: Key Highlights 1Q Financial Highlights • Revenue: • 1.4% growth vs. 1Q 2025 • 12.2% growth when excluding impact of a large, former client • Profitability: • 10% increase in gross profit vs. 1Q 2025, yielding a 25.3% gross margin (a 190 basis point increase vs. prior year) • 2.1% decrease in Adj. EBITDA vs. 1Q 2025, yielding a 17.2% Adj. EBITDA margin (a 60 basis point decrease vs. prior year) • Member engagement: • 0.48% female utilization in 1Q 2026 as compared to 0.46% in the prior year period • 0.48 ART Cycles per Unique Female Utilizer in 1Q 2026 • Operating Cash Flow: • $45.9 million of operating cash flow generated in 1Q 2026 Other Highlights • Share repurchase program: • During 1Q, 5.5 million shares were repurchased for $116.4 million through the November 2025 share repurchase program • Approximately 8.8 million shares have been repurchased cumulatively through the program Note: 1Q reflects the results for the three-month period ending March 31, 2026
P L E A S E R E F E R T O S L I D E 2 F O R T H E S A F E H A R B O R L A N G U AG E R E G A R D I N G T H I S P R E S E N T A T I O N4 1st Quarter 2026 Results Highlights for 3-Month Period Ending March 31, 2026 Revenue Op. Cash Flow $328.5 1Q 2025 1Q 2026 • 1.4% growth vs. 1Q25; 12% when excluding the impact of large, former client • Increase driven by growth in clients and covered lives Contribution from Large, Former Client* $M Adj. EBITDA • 2.1% decrease in Adj. EBITDA vs. 1Q25, as planned investments to expand the features and functionality of the platform more than offset the higher gross profit $57.8 $56.6 1Q 2025 1Q 2026 $M 17.8% margin 17.2% margin $292.7 $49.8 $45.9 1Q 2025 1Q 2026 $M • Successfully maintaining targeted 75+% conversion of Adj. EBITDA to OCF • Decrease reflects timing of working capital items in both periods, as well as customary build in accounts receivable as we establish payment flows for newest clients Gross Profit • 10% increase in gross profit vs. 1Q25 • Gross margin expanded by 190 basis points • Reflects ongoing efficiencies realized in the delivery of our care management services and a decrease in stock- based compensation $75.8 $83.1 1Q 2025 1Q 2026 $M 23.4% gross margin 25.3% gross margin $324.0 as reported +12% *Reflects contribution of $31.3 and $0 in 1Q25 and 1Q26, respectively -2.1% +1.4% +10% -8%
P L E A S E R E F E R T O S L I D E 2 F O R T H E S A F E H A R B O R L A N G U AG E R E G A R D I N G T H I S P R E S E N T A T I O N5 1st Quarter 2026 Results Business Metrics ART Cycles Consumed Clients 1Q 25 1Q 26 1Q 25 1Q 26 Utilization1 • 1Q26 utilization of 0.48% • Longer-term utilization continues within the customary narrow range 0.25% 0.35% 0.45% 0.55% 1Q 24 2Q 24 3Q 24 4Q 24 1Q 25 2Q 25 3Q 25 4Q 25 1Q 26 Female Utilization 15,647595 532 16,160 • The majority of the clients added in the most recent selling season went live in 1Q, with a handful of additional clients expected to launch in 2Q • 3% decrease in ART Cycles vs. prior year period In 000s 1Q 25 1Q 26 7,185 6,695 • 7% increase in average members vs. prior year period • A handful of additional clients are expected to launch in 2Q 1. Represents the member utilization rate for all fertility and family building services, including, but not limited to, ART cycles, initial consultations, IUIs, and genetic testing. For purposes of calculating utilization rates in any given period, the results reflect the number of unique members utilizing the benefit for that period. Individual periods cannot be combined as member treatments may span multiple periods. Avg. Eligible Members
P L E A S E R E F E R T O S L I D E 2 F O R T H E S A F E H A R B O R L A N G U AG E R E G A R D I N G T H I S P R E S E N T A T I O N6 1st Quarter 2026 Results Last Twelve Months Trends LTM Gross Profit LTM Adj. EBITDA LTM OCF • $1.29B in trailing twelve-month revenue, an increase of 6.6% relative to the year ago period LTM Revenue 1Q 25 2Q 25 3Q 25 4Q 25 1Q 26 $B 1Q 25 2Q 25 3Q 25 4Q 25 1Q 26 • $206M in trailing twelve-month operating cash flow, a 1.6% increase from the year ago period $M • $312M in trailing twelve-month gross profit, an increase of 17% relative to the year ago period 1Q 25 2Q 25 3Q 25 4Q 25 1Q 26 $M • $221M in trailing twelve-month Adj. EBITDA, an increase of 7.1% relative to the year ago period 1Q 25 2Q 25 3Q 25 4Q 25 1Q 26 $M $1.29B $221M $312M $206M $1.21B $206M $267M $203M Note: all numbers presented ion this slide include the contribution of the large client who was under a transition of care agreement until June 30, 2025
P L E A S E R E F E R T O S L I D E 2 F O R T H E S A F E H A R B O R L A N G U AG E R E G A R D I N G T H I S P R E S E N T A T I O N7 Balance Sheet and Cash Position • Maintaining balance sheet strength and operational flexibility: • $225 million in cash, cash equivalents and marketable securities as of March 31, 2026 • No debt, and the $200 million revolving credit facility remains undrawn • 5.5 million shares repurchased during the 1st quarter for $116.4 million • Approximately 8.8 million shares were repurchased under the November 2025 program • Ongoing focus on revenue cycle management driving continued improvement in days sales outstanding (DSO) • 72 days outstanding as of March 2026, an improvement of more than 11 days from the year ago period • $266 million in net working capital
P L E A S E R E F E R T O S L I D E 2 F O R T H E S A F E H A R B O R L A N G U AG E R E G A R D I N G T H I S P R E S E N T A T I O N8 1st Quarter 2026 Results Guidance Recap Three Month Period Ending June 30, 2026 Twelve Month Period Ending December 31, 2026 Revenue Net Income Adj. EBITDA $342 - $355 million $25.8 - $28.7 million $58.0 - $62.0 million $1.365 - $1.405 billion $103.7 - $112.3 million $232.0 - $244.0 million Revenue growth 2.7% – 6.6%, or 8.3% - 12.4% excluding the $17.2M of revenue in 2Q 2025 from the large client under a transition agreement through the first half of 2025 5.9% - 9.0%, or 10.1% - 13.3% excluding the $48.5M of revenue in 2025 from the large client under a transition agreement through the first half of 2025 Earnings Per Diluted Share $0.31 - $0.35 $1.23 - $1.34 Adj. Earnings Per Diluted Share $0.50 - $0.53 $1.98 - $2.09
P L E A S E R E F E R T O S L I D E 2 F O R T H E S A F E H A R B O R L A N G U AG E R E G A R D I N G T H I S P R E S E N T A T I O N9 Appendix
P L E A S E R E F E R T O S L I D E 2 F O R T H E S A F E H A R B O R L A N G U AG E R E G A R D I N G T H I S P R E S E N T A T I O N10 Reconciliations of Non-GAAP Financial Guidance (in thousands) Three Months Ending June 30, 2026 Year Ending December 31, 2026 Low High Low High Revenue $342,000 $355,000 $1,365,000 $1,405,000 Net Income $25,800 $28,700 $103,700 $112,300 Add: Depreciation and Amortization 2,500 2,500 11,000 11,000 Stock-based Compensation Expense 21,000 21,000 80,000 80,000 Interest and other income, net (1,600) (1,600) (7,000) (7,000) Provision for income taxes 10,300 11,400 44,300 47,700 Adjusted EBITDA* $58,000 $62,000 $232,000 $244,000 * All of the numbers in the tables above reflect our future outlook as of the date hereof. Net income, Adjusted Net Income and Adjusted EBITDA ranges do not reflect any estimate for other potential activities and transactions, nor do they contemplate any discrete income tax items, including the income tax impact related to equity compensation activity.
P L E A S E R E F E R T O S L I D E 2 F O R T H E S A F E H A R B O R L A N G U AG E R E G A R D I N G T H I S P R E S E N T A T I O N11 Reconciliations of Non-GAAP Financial Guidance (in thousands) Three Months Ending June 30, 2026 Year Ending December 31, 2026 Low High Low High Net Income $25,800 $28,700 $103,700 $112,300 Add: Stock-based Compensation Expense 21,000 21,000 80,000 80,000 Income tax effect of non-GAAP adjustment (5,300) (5,300) (17,000) (17,000) Adjusted Net income* $41,500 $44,400 $166,700 $175,300 Diluted Shares 83,000,000 83,000,000 84,000,000 84,000,000 Adjusted Earnings per Diluted Share $0.50 $0.53 $1.98 $2.09 * All of the numbers in the tables above reflect our future outlook as of the date hereof. Net income, Adjusted Net Income and Adjusted EBITDA ranges do not reflect any estimate for other potential activities and transactions, nor do they contemplate any discrete income tax items, including the income tax impact related to equity compensation activity.
P L E A S E R E F E R T O S L I D E 2 F O R T H E S A F E H A R B O R L A N G U AG E R E G A R D I N G T H I S P R E S E N T A T I O N12 Reconciliations of GAAP to Non-GAAP Financial Measures (in thousands) 1Q 25 2Q 25 3Q 25 4Q 25 1Q26 Net income $15,059 $17,112 $13,864 $12,485 $24,232 Add: Depreciation and amortization 1,108 1,205 1,268 1,367 1,483 Stock-based compensation expense 32,512 32,383 32,173 34,799 19,721 Interest and other income, net (2,367) (2,719) (2,437) (2,632) (1,504) Provision for income taxes 11,478 9,965 10,100 5,369 12,651 Adjusted EBITDA $57,790 $57,946 $54,968 $51,388 $56,583
FAQ
How did Progyny (PGNY) perform financially in Q1 2026?
Progyny reported Q1 2026 revenue of $328.5 million, up 1.4% year over year, and net income of $24.2 million, or $0.29 per diluted share. Gross margin expanded to 25.3%, and Adjusted EBITDA was $56.6 million, reflecting continued profitability.
How did the loss of a large client affect Progyny (PGNY) revenue?
A previously disclosed large client contributed $31.3 million of revenue in Q1 2025 and none in Q1 2026. Excluding this client, Progyny’s Q1 2026 revenue grew 12.2% year over year, highlighting strong underlying business growth despite the non-renewal.
What is Progyny’s (PGNY) guidance for full year 2026?
For 2026, Progyny projects revenue of $1.365–$1.405 billion, net income of $103.7–$112.3 million (or $1.23–$1.34 per diluted share), Adjusted EBITDA of $232.0–$244.0 million, and Adjusted earnings per diluted share of $1.98–$2.09.
How much stock did Progyny (PGNY) repurchase in Q1 2026?
During Q1 2026, Progyny repurchased more than 5.5 million shares of its common stock for $116.4 million. In total, the company bought back 8.8 million shares under its $200 million November 2025 share repurchase program, which is now completed.
What is Progyny’s (PGNY) cash and debt position after Q1 2026?
As of March 31, 2026, Progyny held $225.1 million in cash, cash equivalents and marketable securities and had no debt. It also maintained an undrawn $200 million revolving credit facility, supporting liquidity and financial flexibility.
How are Progyny’s (PGNY) utilization and member metrics trending?
In Q1 2026, Progyny reported 0.48% female utilization versus 0.46% a year earlier, and 15,647 ART cycles compared with 16,160. Average members increased to 7.185 million, up from 6.695 million, reflecting client and covered lives growth.
What is Progyny’s (PGNY) revenue outlook for Q2 2026?
For Q2 2026, Progyny projects revenue of $342.0–$355.0 million, representing growth of 2.7%–6.6% year over year, or 8.3%–12.4% excluding $17.2 million from the former large client’s transition revenue in the prior-year quarter.